Synapticure, a telemedicine company that provides personalized virtual care to individuals living with neurodegenerative diseases, including Alzheimer’s, Parkinson’s, ALS, and others, raised $25 million in a Series A funding round.
B Capital led the investment round with participation from CVS Health Ventures, RA Capital Management, CommonSpirit Health, Nexus NeuroTech Ventures, Google Ventures, Rock Health Capital, and Optum Ventures.
Synapticure also offers virtual mental health support, genetic testing, and guidance related to clinical trials, according to its website.
With fresh funds, Synapticure intends to scale up its partnerships with healthcare payers and providers and accelerate its virtual care solutions across the U.S.
In the official press announcement, Sandra Abrevaya, co-founder and CEO of Synapticure, said: “This investment will enable Synapticure to continue to democratize care for people and their families living with neurodegenerative diseases.”
“With the support of B Capital as well as both new and existing blue-chip investors, I am proud Synapticure works to reach patients in any community across the U.S. living with one of these conditions so they can receive the expert, personalized specialty care they deserve.”
Including the latest funds round, Synapticure has raised a total of $31 million in funding to date.
In 2022, the Chicago-based Synapticure was founded with $6 million in seed funding in a round led by Google Ventures (GV).